Pharmacoeconomic implications of preference toward reference- versus generic-brand antidepressants in primary care

dc.contributor.authorGultekin, Onur
dc.contributor.authorAydin, Volkan
dc.contributor.authorBayram, Dilara
dc.contributor.authorAtac, Omer
dc.contributor.authorAkici, Ahmet
dc.date.accessioned2026-02-06T18:43:27Z
dc.date.issued2024
dc.departmentDoğu Akdeniz Üniversitesi
dc.description.abstractBackground: The prevalence of depression is gradually increasing worldwide with an increasing utilization of antidepressants. Nevertheless, despite their lower costs, generic-brand antidepressants were reported to be less prescribed. We aimed to examine the costs of reference- versus generic-brand antidepressant prescriptions in primary care practice.Methods: This cross-sectional study included electronic prescriptions for adult patients that contained antidepressants (World Health Organization's Anatomical Therapeutic Chemical (ATC) code: N06A), which were generated by a systematically selected sample of primary care doctors (n = 1431) in Istanbul in 2016. We examined the drug groups preferred, the reference- versus generic-brand status, and pharmacotherapy costs.Findings: The majority of the prescriptions were prescribed for women (71.8%), and the average age of the patients was 53.6 +/- 16.2 years. In prescriptions with a depression-related indication (n = 40 497), the mean number and cost of drugs were 1.5 +/- 1.0 and 22.7 +/- 26.4 United States Dollar ($) per prescription, respectively. In these prescriptions, the mean number and cost of antidepressants per encounter were 1.1 +/- 0.2 and $17.0 +/- 13.2, respectively. Reference-brand antidepressants were preferred in 58.2% of depression-related prescriptions, where the mean cost per prescription was $18.3 +/- 12.4. The mean cost per prescription of the generics, which constituted 41.8% of the antidepressants in prescriptions, was $15.1 +/- 11.4. We found that if the generic version with the lowest cost was prescribed instead of the reference-brand, the mean cost per prescription would be $12.9 +/- 11.2.Conclusions: Our study highlighted the substantial pharmacoeconomic impact of generic-brand antidepressant prescribing, whose preference over reference-brands could reduce the cost of antidepressant medication treatment by 17.5% in primary care, which could be approximately doubled if the cheapest generic antidepressant had been prescribed.
dc.description.sponsorshipThe authors would like to thank the Ministry of Health of the Republic of Turkey and its authorities for their contribution to the provision of data and to the study.
dc.identifier.doi10.1017/S1463423624000276
dc.identifier.issn1463-4236
dc.identifier.issn1477-1128
dc.identifier.orcid0000-0001-8984-9673
dc.identifier.orcid0000-0001-7037-353X
dc.identifier.orcid0000-0003-0527-0512
dc.identifier.pmid39301599
dc.identifier.scopus2-s2.0-85204512046
dc.identifier.scopusqualityQ1
dc.identifier.urihttps://doi.org/10.1017/S1463423624000276
dc.identifier.urihttps://hdl.handle.net/11129/13621
dc.identifier.volume25
dc.identifier.wosWOS:001316034500001
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakPubMed
dc.indekslendigikaynakScopus
dc.language.isoen
dc.publisherCambridge Univ Press
dc.relation.ispartofPrimary Health Care Research & Development
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WoS_20260204
dc.subjectantidepressive agents
dc.subjectdrug utilization
dc.subjectgeneric drugs
dc.subjectpharmacoeconomics
dc.subjectprimary health care
dc.titlePharmacoeconomic implications of preference toward reference- versus generic-brand antidepressants in primary care
dc.typeArticle

Files